Trial Profile
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAPRI
- 27 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 27 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.